Flibanserin and Female Sexual Desire
|
|
- Eileen Norman
- 6 years ago
- Views:
Transcription
1 Rx Photo Pixland / thinkstockphotos.com E Editor s note: The Rx column is intended to objectively inform and report on new developments in pharmacologic treatments and medical devices. Because in many cases the products being reported on have not been on the market for an extended period, the literature cited is likely to include trials sponsored by the pharmaceutical manufacturer(s). Flibanserin and Female Sexual Desire Heidi Collins Fantasia According to the World Health Organization, sexual health is a multifaceted state of physical, emotional, mental, and social well-being in relation to sexuality, and it includes not only the absence of dysfunction but also having pleasurable sexual experiences (2015). Sexual health Abstract Female hypoactive sexual desire disorder (HSDD) is one type of sexual problem that can affect women. It is characterized by low or absent sexual desire that cannot be attributed to another cause and results in difficulty in interpersonal relationships. HSDD is not well understood, and women may not report symptoms of difficulties to their health care providers. In August 2015, the U.S. Food and Drug Administration approved flibanserin, a nonhormonal oral medication for the treatment of HSDD in premenopausal women. Flibanserin is the only currently available pharmacologic treatment for HSDD. This article will provide an overview of flibanserin, including potential adverse reactions, special considerations for use, and implications for nursing practice. Keywords female hypoactive sexual desire disorder female sexual interest/arousal disorder flibanserin nwhjournal.org 2016, AWHONN 309
2 Rx Heidi Collins Fantasia, PhD, RN, WHNP-BC, is an assistant professor in the College of Health Sciences, School of Nursing at the University of Massachusetts Lowell in Lowell, MA, and a nurse practitioner at Health Quarters in Beverly, MA. The author reports no conflicts of interest or relevant financial relationships. Address correspondence to: heidi_fantasia@uml.edu. disorders, including disorders of low desire, have complex etiologies that have been difficult to accurately define and treat (Nappi, 2015). Researchers have estimated that approximately 12% of women will experience some type of self-reported sexual problem in their lifetime, including problems with sexual desire (Shifren, Monz, Russo, Segreti, & Johannes, 2008). Hypoactive sexual desire disorder (HSDD) is one type of sexual problem reported by women, although the exact incidence is difficult to estimate because of lack of validated measurement Sexual health is a multifaceted state of physical, emotional, mental, and social well-being in relation to sexuality, and it includes not only the absence of dysfunction but also having pleasurable sexual experiences tools, lack of clinical experts, and reluctance of women to discuss sexual concerns with their health care providers (DeRogatis et al., 2011). Female HSDD is characterized by low or absent interest in sex that results in personal distress and difficulty within intimate relationships (American Psychiatric Association, 2013; Kingsberg & Woodard, 2015). Until recently there have been no approved pharmacologic therapies to treat HSDD in women. In August 2015, the U.S. Food and Drug Administration (FDA) approved flibanserin (Addyi, Valeant Pharmaceuticals, Laval, Quebec, Canada) as the first medication to treat HSDD in premenopausal women (FDA, 2015). This column will review flibanserin s mechanism of action and adverse effects, special considerations for use, and implication for nurses who work with women experiencing HSDD. (Note: Recent revisions to the Diagnostic and Statistical Manual of Mental Disorders [American Psychiatric Association, 2013] changed the diagnosis of HSDD to female sexual interest/ arousal disorder [Joffe et al., 2016], but for this column the term HSDD is used.) Controversy Surrounding FDA Approval The approval of the first pharmacologic treatment for HSDD in women has not been without controversy (Joffe et al., 2016). First, the prevalence of HSDD has been questioned. The prevalence of any female sexual problem has been reported at more than 40% by some researchers, although this figure is from a study that was published more than 16 years ago; the researchers did not specifically examine HSDD but instead included it among many other sexual complaints (Laumann, Paik, & Rosen, 1999). In addition to questions about the prevalence of HSDD, some health care providers have questioned whether this disorder has been created merely to sell a product and increase pharmaceutical profits (Meixel, Yanchar, & Fugh-Berman, 2015). Because there is no established norm for sexual desire, others have questioned whether HSDD is a condition that needs treatment or is a normal variant on a continuum of sexual expression and interest (Quigley, 2015). These views conflict with those of clinicians and researchers who believe that women s sexual health has been long overlooked and recognize HSDD as a prevalent condition that has not received enough attention (Kingsberg & Woodard, 2015; Nappi, 2015). An additional concern that has been raised is the possibility of off-label use in populations of women with a broader range of health conditions than were initially included in clinical trials (Gellad, Flynn, & Alexander, 2015). Women who participated in the clinical trials were excluded if they were taking multiple different medications or had pre-existing medical conditions. Therefore, to meet the criteria for HSDD and treatment with flibanserin, a woman must be experiencing symptoms of HSDD that are not caused by a pre-existing medical or psychiatric condition, medication/substance use, or difficulty within her relationship (Sprout Pharmaceuticals, Inc., 2015). Because no postmenopausal women were included in clinical trials, the FDA has approved flibanserin for use in only premenopausal women (Sprout Pharmaceuticals, Inc., 2015), thus excluding a large population of women who may be experiencing low sexual desire. When all of these criteria are considered, the population of women who are considered appropriate candidates according to the FDA approval decision becomes narrower. This increases the chance that health care providers might choose to prescribe this medication for a broader population of women than was 310 Nursing for Women s Health Volume 20 Issue 3
3 Photo Zeljko Bozic / thinkstockphotos.com initially intended, which may increase the risk of adverse reactions (Gellad et al., 2015). Overview of Flibanserin The exact mechanism of flibanserin in the treatment of HSDD among premenopausal women is not completely known. Flibanserin acts on serotonin and dopamine neurotransmitter systems that are involved in the sexual response system of the brain (Basson, Driscoll, & Correia, 2015; Stahl, Sommer, & Allers, 2011; Uphouse, 2014). Flibanserin initially underwent trials as an antidepressant but failed to receive FDA approval because of lack of efficacy. However, during the antidepressant drug trials it was noted that flibanserin had prosexual effects. This backward translation of side effects led to a new FDA application with the indication of flibanserin for low sexual desire (Basson et al., 2015; Gellad et al., 2015). Dosage and Administration Flibanserin is supplied as a pink oval tablet for oral use. The recommended dose of flibanserin is 100 mg at bedtime. It is recommended for bedtime use only because of risks of hypotension, syncope, somnolence, and sedation. Taking the medication during waking hours could increase the risk of injury if central nervous system symptoms were to occur during typical activities during awake-time hours such as driving, work, exercise, or other activities for which concentration and alertness are necessary. Missed doses should not be doubled or taken when the woman remembers. Instead, the next dose should be taken on the next day at bedtime (Sprout Pharmaceuticals, Adverse Reactions There are possible adverse reactions that are important to consider. The FDA has required flibanserin to carry a black box warning to highlight the most significant of these potential reactions. Hypotension, possibly resulting in syncope, has occurred. Specifically, if flibanserin is taken with alcohol, the risk of severe hypotension and syncope increases; therefore; women who are taking flibanserin must not drink any alcohol for the duration of treatment. Additional central nervous system effects may include dizziness, fatigue, and sedation (Gellard et al., 2015; Jaspers et al., 2016). During clinical trials, female mice developed malignant mammary tumors when exposed to dosages up to 10 times the recommended dosage; however, the clinical significance of this in humans is unknown (Sprout Pharmaceuticals, Drug Interactions Flibanserin interacts with medications that are classified as weak moderate CYP3A4 inhibitors and strong CYP2C19 inhibitors. Both classes of medication affect the metabolism of flibanserin and increase bioavailability, resulting in greater flibanserin levels and potentially an increase in adverse reactions, specifically hypotension and syncope. Examples of strong CYP2C19 inhibitors include protein pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, and antifungals. CYP3A4 inhibitors include oral contraceptives, cimetidine, ranitidine, fluconazole, grapefruit juice, and antibiotics such as ciprofloxacin and erythromycin (Sprout Pharmaceuticals, Contraindications In addition to the contraindications of alcohol and medications that may increase flibanserin levels, flibanserin should not be used by women with any hepatic impairment, even mild. Elevated flibanserin levels have occurred in women with hepatic impairment, and this has the potential to increase the risk of adverse events such as hypotension and syncope (Sprout Pharmaceuticals, Special Populations Flibanserin is approved for use in premenopausal women. There are no human data on safety in pregnancy. In animal studies fetal toxicity occurred during episodes of maternal toxicity from higher-than-recommended dosages. Animal models may not accurately reflect human safety or harm. Flibanserin is not recommended for pediatric or geriatric use and is not indicated for use during and after the menopause transition. Flibanserin is excreted in animal milk, but data are lacking on human milk. Because of the possibility of drug excretion in human milk and potential sedative effects on the infant, flibanserin is not recommended during lactation (Sprout Pharmaceuticals, Rx June July 2016 Nursing for Women s Health 311
4 Rx Implications for Nurses Diagnosing HSDD is challenging, and nurses must recognize that women may have experienced symptoms of this disorder for years before seeking treatment. Women with HSDD may report a variety of symptoms, including absent or low interest in or desire for sex and/ or inability to respond to sexual stimuli despite describing a healthy relationship with their partner (Kingsberg & Woodard, 2015). Women may feel frustrated and embarrassed and not sure of how to discuss their concerns with their health care provider. It is important to establish a nonjudgmental and supportive environment to facilitate taking a prescription that is dispensed (Sprout Pharmaceuticals, Nurses can help women locate a participating pharmacy and should be aware that it may not be the same pharmacy where a woman s other prescriptions are filled (see Box 1). Education about the risks of using alcohol while taking flibanserin is extremely important. No safe level of alcohol has been established during treatment with flibanserin. It is Education about the risks of using alcohol while taking flibanserin is extremely important complete sexual history and full symptom disclosure (Kingsberg & Woodard, 2015). Because of the potential risk for serious adverse reactions that could result in injury, flibanserin can be prescribed only by health care providers who have participated in pharmaceutical company sponsored training, have completed a knowledge assessment, and have enrolled in the Risk Evaluation and Management Strategy program. The Risk Evaluation and Management Strategy program was a condition necessary for FDA approval of flibanserin (Gellad et al., 2015). Additionally, pharmacies must also complete a similar program, train all pharmacy staff, and counsel women about the risk of alcohol use with each Box 1. Participating Pharmacies important to assess baseline alcohol use and whether abstaining from alcohol for the duration of treatment is possible. A patient provider agreement form has been developed for health care providers and is available at Flibanserin is available only through a restricted Risk Evaluation and Management Strategy program. Not every pharmacy participates in this program. A list of participating pharmacies can be found at or by calling Photo istock Collection / thinkstockphotos.com 312 Nursing for Women s Health Volume 20 Issue 3
5 addyiremsprogrampatientprovider- AgreementForm.pdf (Sprout Pharmaceuticals, This form should be signed by the woman and her health care provider. A copy should be placed in the health record and the informational section given to the woman for reference. Even with education, prescribing restrictions, and agreement forms, concern has been raised regarding whether all women taking flibanserin will be able to completely abstain from alcohol during treatment. Because all adverse effects are not currently known, including all the risks that may be associated with combining flibanserin with alcohol, additional postapproval trials will be conducted (Joffe et al., 2016). Nurses caring for women taking flibanserin should evaluate any knowledge deficits; review understanding of alcohol risks; and discuss signs and symptoms of hypotension, including dizziness, lightheadedness, and syncope. To avoid the potential for injury, women who are experiencing these symptoms should be educated to lie down if possible, seek emergency medical help if the symptoms are severe or do not resolve, and always seek help if the symptoms are associated with a loss of consciousness. Additionally, specific instructions on how to take the medication need to be reviewed. Flibanserin must only be taken at bedtime, so that if hypotension occurs the woman is already lying down or sleeping, which may reduce the chance for falls and injury. Any known or suspected adverse events should be reported to the FDA through the adverse event reporting program (see Box 2). Nurses should review all current prescription and nonprescription medications (including herbal medications and supplements) with women who are considering treatment with flibanserin, because multiple medications have the potential to interact with flibanserin and result in increased bioavailability and adverse events. Women who Box 2. Reporting Adverse Events All health care providers are encouraged to report actual or suspected adverse events to or FDA are taking flibanserin should discuss all their medications (prescription, over the counter, supplements) with their health care provider to identify possible drug interactions. Decisions about whether to begin or continue treatment with flibanserin if use will occur concurrently with medications that have known interactions should be made on an individual basis. It is not fully known how flibanserin works to increase sexual desire, and it may not work for all women. Education should be provided regarding overall efficacy and treatment expectations. In clinical trials women who took flibanserin reported 0.5 to 1.0 more satisfying sexual event per month compared with women in the placebo group, which is a relatively small clinical improvement (Basson et al., 2015). A recent review by Jaspers et al. (2016) concluded that treatment with flibanserin resulted in, on average, one half additional satisfying sexual event per month. A therapeutic effect should be seen after 8 weeks of treatment. Women should be aware that if there is no improvement in symptoms after 8 weeks, then the medication will be discontinued. Increasing the dosage is not an option because of the increased risk of adverse events when the dosage of flibanserin Nurses should review all current prescription and nonprescription medications (including herbal medications and supplements) with women who are considering treatment with flibanserin, because multiple medications have the potential to interact with flibanserin and result in increased bioavailability and adverse events exceeds 100 mg/day (Sprout Pharmaceuticals, Women must understand that for a therapeutic effect to occur, flibanserin must be taken every night; it is not an as needed medication or a female equivalent to medication for male erectile dysfunction. Additionally, women should be advised that in addition to pharmacologic treatment, nonpharmacologic therapies for female sexual dysfunction can be considered, including individual counseling, behavioral and couples therapy, diet and lifestyle modifications, and complementary and alternative therapies such as mindfulness, yoga, and acupuncture (Bradway & Boullata, 2014). As with all new medications, flibanserin will most likely become a toptier (i.e., high-copay) medication for women who have prescription coverage as part of their health insurance. Through December 2016 women may be able to reduce copay costs further through a program offered by Sprout Pharmaceuticals. If women already have health insurance with coverage for prescription medication and meet additional eligibility requirements set forth by the manufacturer, they may be able to obtain a 30-day supply of flibanserin for as low as $20 for a limited number June July 2016 Nursing for Women s Health 313
6 of months. This benefit does not apply to women without commercial health insurance. Out-of-pocket expenses for 30 tablets of flibanserin could be as high as $800 based on early estimates from the manufacturer. Full details of this program and potential costs can be found at Conclusion Although the FDA approval of flibanserin represents a new treatment option for premenopausal women who are experiencing low sexual desire, the availability of this recent pharmacologic treatment is not without controversy. Women who are considering treatment with flibanserin will need to weigh a risk/benefit profile that includes the potential for serious adverse events and relatively small treatment efficacy. Nurses will be an integral part of the health care team for women taking flibanserin in the provision of education, support, reassurance, and assistance with obtaining prescriptions. NWH References American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author. Basson, R., Driscoll, M., & Correia, S. (2015). Flibanserin for low sexual desire in women: A molecule from bench to bed? EBioMedicine, 2(8), doi: /j.ebiom Bradway, C., & Boullata, J. (2014). Pharmacologic therapy for female sexual dysfunction. The Nurse Practitioner, 39(1), doi: /01. NPR c DeRogatis, L. R., Clayton, A. H., Goldstein, A., Lewis-D Agostino, D., Wunderlich, G., & Cotton, D. (2011). ediary and Female Sexual Distress Scale in evaluating distress in hypoactive sexual desire disorder (HSDD). The Journal of Sex Research, 48(6), doi: / Gellad, W. F., Flynn, K. E., Alexander, G. C. (2015). Evaluation of flibanserin: Science and advocacy at the FDA. Journal of the American Medical Association, 314(9), doi: / jama Jaspers, L., Feys, F., Bramer, W. M., Franco, O. H., Leusink, P., & Laan, E. T. M. (2016). Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis. JAMA Internal Medicine, 176(4), doi: / jamainternmed Joffe, H. V., Chang, C., Sewell, C., Easley, O., Nguyen, C., Dunn, S.,... Beitz, J. (2016). FDA approval of flibanserin Treating hypoactive sexual desire disorder. The New England Journal of Medicine, 374, doi: / NEJMp Kingsberg, S. A., & Woodard, T. (2015). Female sexual dysfunction: Focus on low desire. Obstetrics & Gynecology, 125(2), doi: /aog Laumann, E. O., Paik, A., & Rosen, R. C. (1999). Sexual dysfunction in the United States: Prevalence and predictors. Journal of the American Medical Association, 281(6), doi: /jama Meixel, A., Yanchar, E., & Fugh-Berman, A. (2015). Hypoactive sexual desire disorder: Inventing a disease to sell low libido. Journal of Medical Ethics, 41(10), doi: / medethics Nappi, R. E. (2015). Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opinion of Pharmacotherapy, 16(12), doi: / Quigley, M. (2015). Evidence and ethics: Once more into the fray. Journal of Medical Ethics, 41(10), doi: /medethics Shifren, J. L., Monz, B. U., Russo, P. A., Segreti, A., & Johannes, C. B. (2008). Sexual problems and distress in United States women: Prevalence and correlates. Obstetrics & Gynecology, 112(5), doi: /aog.0b013e cdb Sprout Pharmaceuticals, Inc. (2015). Addyi (flibanserin): Highlights of prescribing information. Raleigh, NC: Author. Retrieved from addyi.com/files/addyi-pi pdf Stahl, S. M., Sommer, B., & Allers, K. A. (2011). Multifunctional pharmacology of flibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder. Journal of Sexual Medicine, 8(1), doi: /j x U.S. Food and Drug Administration. (2015). FDA approves first treatment for sexual desire disorder [press release]. Retrieved from fda.gov/newsevents/newsroom/ PressAnnouncements/ucm htm Uphouse, L. (2014). Pharmacology of serotonin and sexual behavior. Pharmacology, Biochemistry, and Behavior, 121, doi: /j. pbb World Health Organization. (2015). Sexual and reproductive health: Defining sexual health. Geneva, Switzerland: Author. Retrieved from who.int/reproductivehealth/topics/ sexual_health/sh_definitions/en/ 314 Nursing for Women s Health Volume 20 Issue 3
Addyi REMS Program Prescriber and Pharmacy Training
Addyi REMS Program Prescriber and Pharmacy Training The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of Addyi outweigh the increased
More informationAddyi (flibanserin) When Policy Topic is covered Coverage of Addyi is recommended in those who meet the following criteria:
Addyi (flibanserin) Policy Number: 5.01.605 Last Review: 10/2018 Origination: 10/2015 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Addyi when
More informationAddyi (filbanserin) REMS Program Prescriber and Pharmacy Training
Addyi (filbanserin) REMS Program Prescriber and Pharmacy Training The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of Addyi outweigh
More informationHypoactive Sexual Desire Disorder: Advances in Diagnosis and Treatment
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationMigraine Headache Prophylaxis in Adolescents
I Migraine Headache Prophylaxis in Adolescents It s estimated that up to 28 percent of adolescents between the ages of 15 and 19 (mostly females) are affected by migraine (Lewis, Yonker, Winner, & Sowell,
More informationErin E. Stevens, MD Chair, Department of Gynecologic Oncology Billings Clinic Cancer Center January 18, 2017
Erin E. Stevens, MD Chair, Department of Gynecologic Oncology Billings Clinic Cancer Center January 18, 2017 Objectives Define what's normal Define female sexual dysfunction Identify the causes of female
More informationSexual dysfunction: Is it all about hormones?
Sexual dysfunction: Is it all about hormones? Angelica Lindén Hirschberg, MD, PhD, Professor Department of Women s and Children s Health, Karolinska Institutet and Karolinska University Hospital, Stockholm,
More informationUpdate on the Essure System for Permanent Birth Control
Update on the Essure System for Permanent Birth Control Heidi Collins Fantasia IIn 2002, the U.S. Food and Drug Administration (FDA) approved Essure (Bayer, Whippany, NJ), a minimally invasive procedure
More informationPsykiatri PCK/Sexologisk Klinik Medication for Female Sexual Dysfunction - where are we?
Medication for Female Sexual Dysfunction - where are we? Annamaria Giraldi, Professor, MD, PHD Sexological Clinic Copenhagen, Denmark Disclosures Eli Lilly - lecturer Boehringer advisory board Pfizer -
More informationAbilify (aripiprazole)
Abilify (aripiprazole) FDA ALERT [04/2005] Abilify is a type of medicine called an atypical antipsychotic. FDA has found that older patients treated with atypical antipsychotics for dementia had a higher
More informationFemale Sexuality Sheryl A. Kingsberg, Ph.D.
Female Sexuality Sheryl A. Kingsberg, Ph.D. Professor of Reproductive Biology Case Western Reserve University School of Medicine Chief, Division of Behavioral Medicine Department of OB/GYN University Hospitals
More informationFlibanserin for Treating Hypoactive Sexual Desire Disorder
pissn: 2288-6478, eissn: 2288-6761 Review Article Flibanserin for Treating Hypoactive Sexual Desire Disorder Jae Hong Sang 1, Tae-Hee Kim 2, Soo Ah Kim 3 1 Department of Obstetrics and Gynecology, Soonchunhyang
More informationA Pharmacist s Guide to Intermezzo
A Pharmacist s Guide to Intermezzo Intermezzo (zolpidem tartrate) is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient
More informationSexuality and Sexual Dysfunction in Women
Sexuality and Sexual Dysfunction in Women Denise M.S. Willers, MD Associate Professor of Obstetrics and Gynecology Washington University School of Medicine Disclosures No financial disclosures to make
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationA New Pharmacologic Treatment for Nausea and Vomiting of Pregnancy
A New Pharmacologic Treatment for Nausea and Vomiting of Pregnancy NNausea and vomiting of pregnancy (NVP) is a common condition that can affect up to 80 percent of all pregnant women. Symptoms can range
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN. LYSODREN (mitotane)
More informationSupplementary Online Content
Supplementary Online Content Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ETM. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic
More informationUnderstanding the Benefits and Risks
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus
More informationWhat is the most important information I should know about midazolam?
midazolam (oral) Pronunciation: mye DAZ oh lam Brand: Versed What is the most important information I should know about midazolam? Midazolam can slow or stop your breathing, especially if you have recently
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationMedication Information for Parents and Teachers
Medication Information for Parents and Teachers Modafinil Provigil Armodafinil Nuvigil General Information About Medication Each child and adolescent is different. No one has exactly the same combination
More informationLow sexual desire: Appropriate use of testosterone in menopausal women
Low sexual desire: Appropriate use of testosterone in menopausal women Low-dose testosterone treatment may be considered for HSDD in carefully selected menopausal women after standard therapies have been
More informationBibliotherapy for Low Sexual Desire among Women: Evidence for Effectiveness. Laurie Mintz, Alexandra Balzer, & Hannah Bush. University of Missouri
Bibliotherapy for Low Sexual Desire among Women: Evidence for Effectiveness Laurie Mintz, Alexandra Balzer, & Hannah Bush University of Missouri Presented at the 118 th Convention of the American Psychological
More informationPOMALYST (pomalidomide) for Previously Treated Multiple Myeloma
POMALYST (pomalidomide) for Previously Treated What is POMALYST? POMALYST (pomalidomide) capsule is an oral immunomodulatory therapy (a thalidomide analogue) indicated for patients with multiple myeloma
More informationAPPROPRIATE USE GUIDE
APPROPRIATE USE GUIDE PRILIGY is indicated for the treatment of premature ejaculation in adult men aged 18 to 64 years 1 * PRILIGY should only be prescribed to patients who meet all the following criteria:
More informationYour Guide to NOCTIVA
Co-pay savings card inside Your Guide to NOCTIVA WARNING: NOCTIVA is a prescription medicine nasal spray that can cause hyponatremia, which is low levels of salt, or sodium, in your blood. Signs of hyponatremia
More informationUpdated: 08/2017 DMMA Approved: 11/2017
Request for Prior Authorization for Therapy to Treat Binge Eating Disorder Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for medications to treat Binge
More informationWhat you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh)
SEE IF YOU CAN BREAK FREE WITH NORTHERA (droxidopa) What you need to know as you begin your treatment for symptomatic neurogenic orthostatic hypotension (noh) Use NORTHERA (droxidopa) is a prescription
More informationADVERSE REACTIONS The most common (>10%) adverse reactions are hypercalcemia, nausea, and diarrhea. (6.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PHOSLYRA safely and effectively. See full prescribing information for PHOSLYRA. PHOSLYRA (calcium
More informationIf you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA
If you wake up to urinate 2 or more times a night, ask your doctor about NOCTIVA IMPORTANT SAFETY INFORMATION WARNING: HYPONATREMIA See full prescribing information for complete boxed warning. NOCTIVA
More informationLOTRONEX and its authorized generic alosetron hydrochloride:
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The Prescribing Program for LOTRONEX TM Prescriber Education Slide Deck PROMETHEUS and the Link Design
More informationPrescriber and Pharmacy Guide for the Opsumit REMS Program
Prescriber and Pharmacy Guide for the Opsumit REMS Program (Risk Evaluation and Mitigation Strategy) including BOXED WARNING for teratogenicity. Risk of teratogenicity Introduction to Opsumit (macitentan)
More informationFlibanserin for Hypoactive Sexual Desire Disorder: Can We Bring Back that Loving Feeling?
Flibanserin for Hypoactive Sexual Desire Disorder: Can We Bring Back that Loving Feeling? Lori D. Watkins, Pharm.D PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Division of Pharmacotherapy,
More informationThe Opioid-Exposed Woman
The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus
More informationPart VI: Summary of the risk management plan by product
Part VI: Summary of the risk management plan by product VI.1 Elements for summary tables in the EPAR VI.1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Hepatotoxic
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationTaking Care: Child and Youth Mental Health TREATMENT OPTIONS
Taking Care: Child and Youth Mental Health TREATMENT OPTIONS Open Learning Agency 2004 TREATMENT OPTIONS With appropriate treatment, more than 80% of people with depression get full relief from their symptoms
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationOne daily pill can help prevent HIV. TRUVADA for PrEP, together with safer sex practices, can mean better protection.
TRUVADA for PrEP is a prescription medicine that can help reduce the risk of getting HIV-1 through sex, when taken every day and used together with safer sex practices. TRUVADA for PrEP is only for people
More information9/30/2016. Data and Women s Preferences Should Inform the Treatment of Hypoactive Sexual Desire Disorder: The Case for Pharmacologic Agents
Data and Women s Preferences Should Inform the Treatment of Hypoactive Sexual Desire Disorder: The Case for Pharmacologic Agents Sources of Evidence for Physiological Mechanisms Modulating Sexual Desire
More informationEfficacy of Flibanserin in Women with Hypoactive Sexual Desire Disorder: Results from the BEGONIA Trial
1 Efficacy of Flibanserin in Women with Hypoactive Sexual Desire Disorder: Results from the BEGONIA Trial Molly Katz, MD,* Leonard R. DeRogatis, PhD, Ronald Ackerman, MD, Parke Hedges, MD, Lynna Lesko,
More informationMISCELLANEOUS AGENTS - ALPHA-AGONISTS
Documentation A. FDA Approved Indications ADHD (Clonidine, Guanfacine) Documentation B. Non-FDA approved, commonly used psychiatric indications 1. Alcohol and opiate dependence 2. Opioid withdrawal 3.
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationMedication Information for Parents and Teachers
Medication Information for Parents and Teachers General Information About Medication Melatonin Each child and adolescent is different. No one has exactly the same combination of medical and psychological
More informationThe only biologic approved to treat SLE: now with multiple delivery options
The only biologic approved to treat SLE: now with multiple delivery options BENLYSTA (belimumab) Autoinjector SC Prefilled syringe IV Intravenous infusion Consider the options: visit Belimumab.com INDICATION
More informationDRUG NAME: Bromocriptine
DRUG NAME: Bromocriptine SYNONYM(S): COMMON TRADE NAME(S): APO-BROMOCRIPTINE, PMS-BROMOCRIPTINE CLASSIFICATION: hormonal agent Special pediatric considerations are noted when applicable, otherwise adult
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationEU Core Safety Profile
EU Core Safety Profile Active Substance: Triazolam Brand Names: HALCION, SOMESE Pharmaceutical form(s)/strength: Tablets RMS: Finland Date: 9 th Dec 2013 Supersedes: 24 th May 2010 4.3. Contraindications
More informationTake CYCLOSET exactly as instructed by your health care provider, and be sure to read the Patient Information section of the package insert.
To help adults control type 2 diabetes along with diet and exercise UNLOCK YOUR INSULIN POTENTIAL A once-daily treatment that works in the brain to help you become more responsive to the insulin in your
More informationThe Medical Letter. on Drugs and Therapeutics. Usual Adult Hypnotic Dose 1,2 Some Adverse Effects Comments Cost 3
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationTHE BIG QUESTION NEW INSIGHTS INTO FEMALE SEXUAL DESIRE DISORDERS SEXUAL DESIRE DISORDERS - COMMON IN WOMEN
NEW INSIGHTS INTO FEMALE SEXUAL DESIRE DISORDERS DISCLOSURES - NIL Dr Rosie King MB BS FAChSHM OUTLINE Prevalence of desire disorders in women Libido and limerence Unrealistic Sexpectations impact of the
More informationOverview Purpose Complete the Qsymia Pharmacy Certification in 3 easy steps:
Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia to ensure the benefits of Qsymia outweigh the increased risk of teratogenicity.
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationPamelor (nortriptyline)
Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor
More informationOverview. Purpose. Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program
Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS)
More informationParticipating Hospital Certification Form
Participating Hospital Certification Form ATTENTION: this Certification Form is only applicable for Free Trial Product Units of ABILIFY MAINTENA (aripiprazole). Instructions: The Authorized Representative
More informationInsomnia Agents (Sherwood Employer Group)
Insomnia Agents (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf Link to
More informationVI.2 Elements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Zolpidem is used for short-term treatment of serious sleep problems that incapacitate or cause people extreme distress. Zolpidem
More informationNeonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)
Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit
More informationPhase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint
For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due
More informationALUNBRIG (brigatinib) Dosing Guide
ALUNBRIG (brigatinib) Dosing Guide INDICATION ALUNBRIG (brigatinib) is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationWomen s Mental Health
Women s Mental Health Linda S. Mullen, MD Director, Women s Mental Health Assistant Professor of Clinical Psychiatry in OB/GYN Columbia University & NewYork Presbyterian Hospital Departments of Psychiatry
More informationBilling & Coding Guide
Billing & Coding Guide CMS established a unique J-code to facilitate reimbursement of ENVARSUS XR J7503 Suggested Coding and Medicare Allowables Coding Overview and Payment Rates Used to Report Code Description
More informationSection I. Short-acting opioid Prior Authorization Criteria
Request for Prior Authorization for Opioid analgesics Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 Requests for opioid analgesics may be subject to prior authorization
More informationTOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE
trazodone TOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE Pharmacodynamics study of what a drug does to the body Studies show that trazodone selectively inhibits neuronal
More informationTofranil and Tofranil-PM (imipramine)
Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:
More informationSexual problems- some basic information
Sexual Problems 1 Soheil A. Hanjani, MD, FACOG, FACS Obstetrics & Gynecology 830 Oak Street Brockton, MA 02301 (508) 583-4961 Fax (508) 583-4732 Soheil.Hanjani@Steward.org www.hanjanimd.com Sexual problems-
More informationPLLR: Subsection 8.3 Females and Males of Reproductive Potential Lynnda Reid US Food and Drug Administration CDER/OND/DBRUP
PLLR: Subsection 8.3 Females and Males of Reproductive Potential Lynnda Reid US Food and Drug Administration CDER/OND/DBRUP American College of Toxicology, November 3, 2013 1 The following presentation
More informationSexuality. The Pharmacologic Treatment of Female Sexual Dysfunction: Future Reality or Wishful Thinking? Risks of Opening the Medicine Cabinet
5 th Annual Meeting of the North American Menopause Society October 5, 4 Washington, DC Low Libido at Midlife: Will the Answer Ever Be in Our Medicine Cabinets? The Pharmacologic Treatment of Female Sexual
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationFor many people, the warnings for a medication can read like the fine print of a home mortgage.
October 16, 2017 HEALTH NEWS Most Consumers Unaware of Dangers in Mixing Alcohol and Common Drugs Patient advocate group NCPIE wants to remind patients and doctors about drug interactions. For many people,
More informationAre you looking for a different option to treat your insomnia?
re you looking for a different option to treat your insomnia? BELSOMR is a prescription medicine for adults who have trouble falling or staying asleep (insomnia). Selected Risk Information Do not take
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationTUSSIGON (hydrocodone bitartrate and homatropine methylbromide) tablets, for oral administration, CII Initial U.S. Approval: 1943
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TUSSIGON safely and effectively. See full prescribing information for TUSSIGON. TUSSIGON (hydrocodone
More informationPrescriber Guide for the Letairis REMS Program
LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationPSYCHOLOGICAL TREATMENT FOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN MEN AND WOMEN
PSYCHOLOGICAL TREATMENT FOR HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN MEN AND WOMEN MARITA McCABE PhD FAPS DIRECTOR INSTITUTE FOR HEALTH AND AGEING SMSNA 207 Annual Scientific Meeting May 2, 207 Boston,
More informationInterventions to Address Sexual Problems in People with Cancer
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Interventions to Address Sexual Problems in People with Cancer L. Barbera, C. Zwaal, D. Elterman, K. McPherson,
More informationHypoactive Sexual Desire Disorder (HSDD)
Hypoactive Sexual Desire Disorder (HSDD) Sharon J. Parish, MD Professor of Medicine in Clinical Psychiatry; Professor of Clinical Medicine 10/07/17 shp9079@med.cornell.edu 1 Conflict Of Interest Disclosure
More informationTreating Insomnia in Primary Care. Judith R. Davidson Ph.D., C. Psych. Kingston Family Health Team
Treating Insomnia in Primary Care Judith R. Davidson Ph.D., C. Psych. Kingston Family Health Team jdavidson@kfhn.net Disclosure statement Nothing to disclose A ruffled mind makes a restless pillow. ~ Charlotte
More informationLIVING. WITH PD. DAVID RYTARY patient since Fighting his symptoms. Embracing his life.
Together, you and your doctor have chosen RYTARY for Parkinson s disease (PD). HERE S HOW TO GET STARTED. LIVING. WITH PD. DAVID RYTARY patient since 2015. Fighting his symptoms. Embracing his life. Do
More informationDecember 2, 2013 Healthy Smile Happy Child Telehealth Presentation Dr. Robert J Schroth
December 2, 2013 Healthy Smile Happy Child Telehealth Presentation Dr. Robert J Schroth umschrot@cc.umanitoba.ca Recent report of an expert working group on Oral Health Care During Pregnancy October 2011
More informationFAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals
FAQ - ARIPIPRAZOLE Educational materials for the Healthcare profesionals Aripiprazole Dr. Reddy's 5, 10, 15 and 30 mg film-coated tablets Aripiprazole is indicated for the treatment up to 12 weeks of moderate-to-severe
More informationINTERNAL MEDICINE FOR PRIMARY CARE: GYNECOLOGY/MEN S UROLOGY/PAIN/PSYCHIATRY. London, United Kingdom The Savoy Hotel, London August 27 30, 2018
INTERNAL MEDICINE FOR PRIMARY CARE: GYNECOLOGY/MEN S UROLOGY/PAIN/PSYCHIATRY London, United Kingdom The Savoy Hotel, London August 27 30, 2018 Monday, August 27th: 7:00 am 7:30 am Registration and Arrival
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationLemilvo Tablets (aripiprazole)
Lemilvo Tablets (aripiprazole) Healthcare Professional Frequently Asked Questions (FAQ) Brochure Bipolar I Disorder in Adolescents Lemilvo (aripiprazole) is indicated for the treatment up to 12 weeks of
More informationUnderstanding Prenatal Alcohol Exposure
Understanding Prenatal Alcohol Exposure Prenatal Alcohol Exposure Causes Birth Defects Alcohol and pregnancy do not mix. Slide 2 The U.S. Surgeon General s Warning The dangers of consuming alcohol during
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationA Guide to Talking to Your Healthcare Provider
A Guide to Talking to Your Healthcare Provider About Moderate to Severe Painful Sex due to Menopause 1 What could be causing my painful sex? 2 Is this a common problem? 3 Is this serious enough to be considered
More informationNevirapine 200mg Tablet WHOPAR part 3 May 2005 Updated: May 2016 PACKAGE LEAFLET
PACKAGE LEAFLET PACKAGE LEAFLET Read this entire leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your
More informationMaternal Mental Health: Risk Factors, Ramifications, and Roles. Anna Glezer MD UCSF Assistant Clinical Professor Founder, Mind Body Pregnancy
Maternal Mental Health: Risk Factors, Ramifications, and Roles Anna Glezer MD UCSF Assistant Clinical Professor Founder, Mind Body Pregnancy Disclosures None Objectives for Today Review major maternal
More information